

Revision date: 15-Dec-2006 Version: 1.1 Page 1 of 7

## IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

**Material Name: Famotidine Chewable Tablets** 

Trade Name: Pepcid Duo Chemical Family: Mixture

**Intended Use:** Pharmaceutical product used for gastrointestinal disorders.

## 2. COMPOSITION/INFORMATION ON INGREDIENTS

### **Hazardous**

Ingredient	CAS Number	EU EINECS List	%
Famotidine	76824-35-6	Not listed	10 mg***
Calcium carbonate	1317-65-3	215-279-6	*
Starch	9005-25-8	232-679-6	*
Sucrose	57-50-1	200-334-9	*
Magnesium stearate	557-04-0	209-150-3	*
Ferric oxide red	1309-37-1	215-168-2	*

Ingredient	CAS Number	<b>EU EINECS List</b>	%
Hydroxypropyl cellulose	9004-64-2	Not listed	*
Hypromellose	9004-65-3	Not listed	*
Lactose Monohydrate	64044-51-5	Not listed	*
Magnesium hydroxide	1309-42-8	215-170-3	*
Peppermint flavor	8006-90-4	Not listed	*
Sodium Lauryl Sulfate	151-21-3	205-788-1	*
Cellulose Acetate	9004-70-0	Not listed	*
Flavor blend	NOT ASSIGNED	Not listed	*

Additional Information: \* Proprietary

\*\*\* per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

# 3. HAZARDS IDENTIFICATION

**Appearance:** Pink, round tablet

Statement of Hazard: May cause harm to breastfed babies.

**Additional Hazard Information:** 

Short Term: Not acutely toxic Not an eye irritant Not a skin irritant (based on components)

Material Name: Famotidine Chewable Tablets

Page 2 of 7
Revision date: 15-Dec-2006

Version: 1.1

**Known Clinical Effects:** Adverse effects most commonly reported in clinical use include headache, nausea and

gastrointestinal disturbances. Occasional, transient changes reported in liver function tests, but no liver damage seen. Individuals sensitive to this material or other materials in its chemical

class may develop allergic reactions. Secreted in human breast milk.

EU Indication of danger: Not classified

**EU Risk Phrases:** 

R64 - May cause harm to breastfed babies.

**Note:** This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

## 4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

# 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

## 6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

**Measures for Environmental** 

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

Material Name: Famotidine Chewable Tablets Page 3 of 7 Revision date: 15-Dec-2006 Version: 1.1

**General Handling:** If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with

eyes, skin, and clothing.

**Storage Conditions:** Store as directed by product packaging.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Calcium carbonate

**OSHA - Final PELS - TWAs:**  $= 15 \text{ mg/m}^3 \text{ TWA}$ total

 $= 5 \text{ mg/m}^3 \text{ TWA}$ 

= 10 mg/m<sup>3</sup> TWA **Australia TWA** 

Starch

**OSHA - Final PELS - TWAs:**  $= 15 \text{ mg/m}^3 \text{ TWA}$ total

 $= 5 \text{ mg/m}^3 \text{ TWA}$ **ACGIH Threshold Limit Value (TWA)**  $= 10 \text{ mg/m}^3 \text{ TWA}$ 

**Australia TWA**  $= 10 \text{ mg/m}^3 \text{ TWA}$ 

Sucrose

 $= 15 \text{ mg/m}^3 \text{ TWA}$ **OSHA - Final PELS - TWAs:** total

 $= 5 \text{ mg/m}^3 \text{ TWA}$ **ACGIH Threshold Limit Value (TWA)**  $= 10 \text{ mg/m}^3 \text{ TWA}$  $= 10 \text{ mg/m}^3 \text{ TWA}$ 

Magnesium stearate

**Australia TWA** 

**ACGIH Threshold Limit Value (TWA)**  $= 10 \text{ mg/m}^3 \text{ TWA}$ except stearates of toxic metals

**Australia TWA**  $= 10 \text{ mg/m}^3 \text{ TWA}$ 

Ferric oxide red

**OSHA - Final PELS - TWAs:**  $= 10 \text{ mg/m}^3 \text{ TWA}$ **ACGIH Threshold Limit Value (TWA)**  $= 5 \text{ mg/m}^3 \text{ TWA}$  $= 5 \text{ mg/m}^3 \text{ TWA}$ **Australia TWA** 

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.

**Personal Protective Equipment:** 

Hands: Not required for the normal use of this product. Wear protective gloves when working with

large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is

possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit

(OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

exposures to below the OEL.

# 9. PHYSICAL AND CHEMICAL PROPERTIES:

**Physical State:** Pink Tablet Color: Molecular Formula: Mixture Molecular Weight: Mixture

Material Name: Famotidine Chewable Tablets

Page 4 of 7
Revision date: 15-Dec-2006

Version: 1.1

# 10. STABILITY AND REACTIVITY

**Stability:** Stable under normal conditions of use.

Conditions to Avoid: None known Incompatible Materials: None identified

# 11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

### Acute Toxicity: (Species, Route, End Point, Dose)

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

Starch

Mouse IP LD50 6600 mg/kg

**Famotidine** 

Rat Oral LD50 4049 mg/kg
Rat Intravenous LD50 254 mg/kg
Rat Intraperitoneal LD50 800 mg/kg
Mouse Oral LD50 4686 mg/kg
Mouse Intravenous LD50 254 mg/kg

Magnesium hydroxide

Rat Oral LD50 8500 mg/kg

Rat Intraperitoneal LD50 2780 mg/kg

Lactose Monohydrate

Rat Oral LD 50 29700 mg/kg

**Sodium Lauryl Sulfate** 

Rat Oral LD 50 1288 mg/kg

Rat Intraperitoneal LD 50 210 mg/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Hypromellose

Rat Oral LD50 > 10,000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

<u>Irritation / Sensitization: (Study Type, Species, Severity)</u>

Magnesium hydroxide

Eye Irritation Rabbit Moderate

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

**Sodium Lauryl Sulfate** 

3 Day(s) Rat Oral 75 mg/kg LOAEL Liver, Blood

Page 5 of 7

**Material Name: Famotidine Chewable Tablets** 

Revision date: 15-Dec-2006 Version: 1.1

### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

#### **Famotidine**

Reproductive & Fertility Rat Intravenous 200 mg/kg/day NOAEL Fertility

Reproductive & Fertility Rat Oral 2000 mg/kg/day NOAEL Fertility

Embryo / Fetal Development Rabbit Intravenous 200 mg/kg/day LOAEL Maternal Toxicity, Fetotoxicity

Embryo / Fetal Development Rabbit Oral 500 mg/kg/day NOAEL Not Teratogenic Embryo / Fetal Development Rat Oral 2000 mg/kg/day NOAEL Not Teratogenic

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### **Famotidine**

Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative with activation

In Vivo Micronucleus Mouse Negative

In Vivo Chromosome Aberration Mouse Negative

#### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### **Famotidine**

92 Week(s) Mouse Oral 2000 mg/kg/day NOAEL Not carcinogenic 106 Week(s) Rat Oral 2000 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

See below

Ferric oxide red

IARC: Group 3

## 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

## 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

## 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

EU Indication of danger: Not classified

**EU Risk Phrases:** 

Material Name: Famotidine Chewable Tablets

Page 6 of 7
Revision date: 15-Dec-2006

Version: 1.1

R64 - May cause harm to breastfed babies.

#### OSHA Label:

May cause harm to breastfed babies.

## **Canada - WHMIS: Classifications**

### WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

## **Famotidine**

Australia (AICS): Present
Standard for the Uniform Scheduling Schedule 2
for Drugs and Poisons: Schedule 4

## **Calcium carbonate**

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
215-279-6

## Starch

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-679-6

### **Sucrose**

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS List

200-334-9

### Hydroxypropyl cellulose

Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present

### Hypromellose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling
for Drugs and Poisons:

XU

Present

Schedule 4

# Magnesium stearate

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present

Material Name: Famotidine Chewable Tablets

Page 7 of 7
Revision date: 15-Dec-2006

Version: 1.1

**EU EINECS List** 209-150-3

**Lactose Monohydrate** 

Australia (AICS): Present

Magnesium hydroxide

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
215-170-3

Peppermint flavor

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present

**Sodium Lauryl Sulfate** 

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentEU EINECS List205-788-1

**Cellulose Acetate** 

Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present

Ferric oxide red

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentEU EINECS List215-168-2

# **16. OTHER INFORMATION**

**Reasons for Revision:** Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard

Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 -

Stability and Reactivity. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

**End of Safety Data Sheet**